Latest research on Optivar

Azelastine, a phthalazine derivative, is an antihistamine and mast cell stabilizer available as a nasal spray for hay fever and as eye drops for allergic conjunctivitis. Azelastine is also available as a combination product of azelastine hydrochloride and fluticasone propionate called Dymista™. Dymista™ is indicated in patient over 12 years old for symptomatic relief of seasonal allergic rhinitis.

Latest findings

Neurons were imaged using an Olympus IX70 inverted microscope with a 60x 1.4NA objective or 40x 0.85NA objective with 1.5x Optivar. [source, 2016]
Our aim was to assess the efficacy of MP29-02* (a novel intranasal formulation of Azelastine Hydrochloride [AZE] and Fluticasone propionate [FP] in an advanced delivery system) in seasonal AR (SAR) patients presenting with nasal congestion or ocular itch predominantly compared to AZE, FP or placebo (PLA) nasal sprays. [source, 2015]
GFP and bright field images of representative areas were taken at 40X magnification with image capture set at LD Plan-Neo Fluor (40X/0.6X Phz Korr) and with 1.6X Optivar. [source, 2015]
Each flat mount was imaged using Zeiss Axiovision software under two or three channels, depending on the experiment, using the 10X objective and 1.6x Optivar. [source, 2015]
Dymista (MP29-02*) is a novel intranasal formulation of Azelastine Hydrochloride (AZE) and Fluticasone propionate (FP) in an advanced delivery system with a well-documented effect on allergic rhinitis. [source, 2015]
The therapy today is not defined so many type of therapy are used by the clinician so the academy try to establish a rule to treat this rhinitis so actually are in study the treatment of such rhinitis with an association between a topical steroid, Fluticasone propionate with a topical antihistamine Azelastine Hydrochloride. the primary results are satisfactory in the treatment of NARES. [source, 2015]
Four previously published trials assessed the efficacy of MP29-02* (a novel intranasal formulation of Azelastine Hydrochloride (AZE) and Fluticasone propionate (FP) in an advanced delivery system) in seasonal allergic rhinitis (SAR) [1,2]. [source, 2015]
MP29-02* is a novel intranasal formulation of Azelastine Hydrochloride (AZE) and Fluticasone propionate (FP) in an advanced delivery system. [source, 2015]
The efficacy of MP29-02* (a novel intranasal formulation of Azelastine Hydrochloride [AZE] and Fluticasone propionate [FP] in an advanced delivery system) in providing overall nasal and ocular symptom relief vs AZE, FP or placebo (PLA) has been assessed. [source, 2015]
MP29-02, comprising Azelastine Hydrochloride, Fluticasone propionate and a novel formulation in a single spray, is the newest addition to the AR treatment arsenal and is promising in this regard [39, 42]. [source, 2015]